ストックスクリーナーアプリを入手
95.70
0.76%
-0.73
Celcuity Inc (CELC) 最新ニュース
Celcuity Inc (CELC) Stock News Today - TradingKey
Celcuity (CELC) Q2 2026 Earnings Call Transcript - AOL.com
CELC Stock Records Worst Day Ever After Late-Stage Breast Cancer Trial Results — What’s Driving The Selloff? - Stocktwits
Celcuity (CELC) Quarter in Focus: EPS Comes in Below Forecast in the Current Update; Closing Move: Shares Move 2.79% Down in the Available RecordEarnings Weakness Phase - vinanet.vn
E Fund Management Co. Ltd. Purchases New Holdings in Celcuity, Inc. $CELC - MarketBeat
Celcuity (NASDAQ: CELC) insider updates stock holdings - Stock Titan
Craig-Hallum Maintains Celcuity(CELC.US) With Buy Rating, Cuts Target Price to $173 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Celcuity's (CELC) "Market Outperform" Rating Reiterated at Citizens Jmp - MarketBeat
Celcuity awaits FDA review for second factory to launch cancer drug - Endpoints News
Guggenheim raises Celcuity stock price target on drug pricing data By Investing.com - Investing.com Nigeria
Guggenheim raises Celcuity stock price target on drug pricing data - Investing.com
H.C. Wainwright reiterates Celcuity stock rating on pricing update - Investing.com
H.C. Wainwright reiterates Celcuity stock rating on pricing update By Investing.com - Investing.com South Africa
Getting To A First Product Approval With Celcuity's Brian Sullivan｜Business Of Biotech - finance.biggo.com
Citizens reiterates Celcuity stock rating ahead of drug launch By Investing.com - Investing.com South Africa
Citizens reiterates Celcuity stock rating ahead of drug launch - Investing.com
Bronstein, Gewirtz & Grossman, LLC Encourages Celcuity Inc. (CELC) Investors to Inquire about Securities Investigation - The National Law Review
Brian Sullivan: The $20 Million Bet That Resurrected Pfizer's Shelved Cancer Drug - finance.biggo.com
Is Celcuity (CELC) A Bargain As Losses Widen Ahead Of Its First Launch? - Yahoo Finance
How Investors May Respond To Celcuity (CELC) Winning FDA Nod For Revtopik Amid Wider Quarterly Loss - Yahoo Finance
The Bull Case For Celcuity (CELC) Could Change Following Revtopik’s FDA Approval And NCCN Category 1 Status - simplywall.st
Celcuity (NASDAQ:CELC) Stock Rating Lowered by Wall Street Zen - MarketBeat
Needham cuts Celcuity stock price target on updated revenue model By Investing.com - Investing.com Australia
Celcuity Stock Price Forecast. Should You Buy CELC? - StockInvest.us
Celcuity (NASDAQ:CELC) Releases Quarterly Earnings Results, Misses Estimates By $0.28 EPS - MarketBeat
H.C. Wainwright Maintains Celcuity(CELC.US) With Buy Rating, Maintains Target Price $155 - Moomoo
Celcuity (CELC) Q2 2026 Ergebniskonferenz: REVTORPYK-Markteinführung für Ende Q3 geplant - TradingKey
Celcuity (CELC) Q2 2026 Earnings Call: REVTORPYK Launch Set for Late Q3 - TradingKey
Celcuity's (CELC) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Celcuity (NASDAQ:CELC) Shares Gap Down on Disappointing Earnings - MarketBeat
Celcuity remains a Buy as FDA approval and stro... - Pluang
Stifel cuts Celcuity stock price target on refined market model - Investing.com
Stifel cuts Celcuity stock price target on refined market model By Investing.com - Investing.com Australia
Celcuity (NASDAQ:CELC) Given New $140.00 Price Target at Needham & Company LLC - MarketBeat
Celcuity: REVTORPYK Is Now A Commercial Story (NASDAQ:CELC) - Seeking Alpha
Celcuity (NASDAQ:CELC) Given New $150.00 Price Target at Stifel Nicolaus - MarketBeat
Celcuity Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Celcuity Analysts Slash Their Forecasts After Q2 Loss - Benzinga
Celcuity Inc. Stock 12‑Month Price Target Cut to $160.64, Implies 85% Upside - TradingView
Needham cuts Celcuity stock price target on updated revenue model - Investing.com
Celcuity Inc. Stock 12‑Month Price Target Cut to $162.18, Implies 87% Upside - TradingView
Celcuity Q2 Net Loss Widens to $73.6M as R&D Spending Rises - minichart.com.sg
CELC|Celcuity Inc|Price:91.810|Chg%:-0.190 - TradingKey
CELC SWOT Analysis: Key Insights from 10-Q Filing - GuruFocus
CELCUITY INC. : JEFFERIES RAISES TARGET PRICE TO $163 FROM $153 - Moomoo
Celcuity Q2 Adjusted Loss Widens - Moomoo
Celcuity Q2 2026 Earnings Call Transcript - MarketBeat
CELC INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Celcuity Inc. - ACCESS Newswire
CELCUITY INC. : NEEDHAM CUTS TARGET PRICE TO $140 FROM $157 - Bitget
Celcuity Q2 Earnings Call Highlights - MarketBeat
CELCUITY ($CELC) Releases Q2 2026 Earnings - Quiver Quantitative
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):